Trisenox® in Women With Metastatic Endometrial Cancer (NRR)
A Phase II Trial of Trisenox in Women With Recurrent or Metastatic Endometrial Adenocarcinoma
Sponsor: Cephalon
Terminated
Accrual was very low. No subject had been enrolled in a year.
Other terminated trials from Cephalon
Other Endometrial Carcinoma trials with similar outcome
A PHASE2 clinical study on Endometrial Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Cephalon and has accumulated 8 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 3 earlier versions
-
Jul 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Jul 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Mar 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cephalon
- UNC Lineberger Comprehensive Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .